17,028 Shares in Takeda Pharmaceutical Company Limited (NYSE:TAK) Bought by Franklin Resources Inc.

Franklin Resources Inc. acquired a new stake in Takeda Pharmaceutical Company Limited (NYSE:TAK) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 17,028 shares of the company’s stock, valued at approximately $244,000.

Several other large investors also recently modified their holdings of TAK. Public Employees Retirement System of Ohio acquired a new stake in Takeda Pharmaceutical in the third quarter valued at $601,000. Verition Fund Management LLC acquired a new stake in shares of Takeda Pharmaceutical in the 3rd quarter valued at about $1,533,000. HighTower Advisors LLC lifted its position in shares of Takeda Pharmaceutical by 199.5% during the third quarter. HighTower Advisors LLC now owns 122,587 shares of the company’s stock worth $1,744,000 after purchasing an additional 81,653 shares during the last quarter. XTX Topco Ltd acquired a new position in Takeda Pharmaceutical in the third quarter worth about $957,000. Finally, Creative Planning increased its holdings in Takeda Pharmaceutical by 46.3% in the third quarter. Creative Planning now owns 157,630 shares of the company’s stock valued at $2,242,000 after buying an additional 49,871 shares during the last quarter. 9.17% of the stock is currently owned by institutional investors and hedge funds.

Takeda Pharmaceutical Trading Up 0.5 %

NYSE:TAK opened at $13.24 on Thursday. Takeda Pharmaceutical Company Limited has a 52 week low of $12.57 and a 52 week high of $15.08. The company has a quick ratio of 0.77, a current ratio of 1.28 and a debt-to-equity ratio of 0.64. The company has a market cap of $42.13 billion, a PE ratio of 22.83, a P/E/G ratio of 0.25 and a beta of 0.51. The business’s 50 day moving average is $13.54 and its two-hundred day moving average is $13.87.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.